FDA Approves Nyxoah Genio 2.1 For Use in DREAM Pivotal Study

Genio 2.1’s upgrades are entirely related to the external components of the Genio system, as the implantable stimulator remains unchanged.

Related Keywords

United States , Olivier Taelman , Drug Administration ,